Abstract
The elimination of most drugs and their metabolites is completely or partially dependent on renal excretion. Pharmacologie action is related to free drug concentration achieved at tissue receptor sites. To avert drug accumulation and possible toxicity, proper consideration must be taken when prescribing dosage regimens for patients with renal failure. Awareness of basic pharmacokinetic and pharmacodynamic principles is necessary to understand the alterations in drug metabolism and elimination that occur in uremia (1, 2). Typically, dialysis patients receive more than eight different medications (2). Adverse drug reactions occur more frequently in patients with renal insufficiency compared to nonazotemic hospitalized patient (3). This chapter addresses the principles relating to rational drug therapy in dialysis patients
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Golper TA, Bennett WM: Altering drug dose in liver and kidney diseases, in Handbook of Drug Therapy in Liver and Kidney Disease, edited by Schrier R, Gambertoglio J. Boston, Little Brown, 1991, p 1
Bennett WM: Adjustment of drug dosage in patiejnts with renal insufficiency. in Textbookof Internal Medicine, edited by Kelley WM, New York, Lippincott, 1991. p 763
Jick H: Adverse drug effects in relation to renal function. Am J Med 62: 514, 1977
Benet LZ, Massoud N: Pharmacokinetics. in Pharmacokinetic Basis for Drug Treatment, edited by Benet LZ, Massoud N, Gambertoglio JG, New York, Raven, 1984, p 1
Ritschel WA: Handbook of Basic Pharmacokinetics — Including Clinical Applications, 3rd Edition. Hmilton, Drug Intelligence Press Inc, 1986, p 163
Sachs EF, Hurwitz FJ, Bloch HM, Milne FJ: Pancreatic exocrine hypofunction in the wasting syndrome of end-stage renal disease. Am J Gastroenterol 78, 170, 1983
Ochs HR, Greenblatt DJ, Bodem G, Dengler HJ: Disease-related alterations in cardiac glycoside disposition. Clin Pharmacokinet 7: 434, 1982
Gibaldi M: Drug distribution in renal failure. Am J Med 62:471, 1977
Reidenberg MM: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 62: 466, 1977
Gulyassy PF, Depner TA: Impaired binding of drugs and endogenous ligands in renal disease. Am J Kidney Dis 2: 578, 1983
McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98: 730, 1981
Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33: 996, 1988
Boobis SW: Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 22: 147, 1977
Maher JF: Principles of dialysis and dialysis of drugs. Am J Med 62: 475, 1977
Golper TA, Bennett WM: Drug visage in dialysis patients, in Clinical Dialysis, 2nd Edition, edited by Nissenson A, Fine R, Gentile D, Norwalk, Appleton-Lange, 1988, p 608
Vos MC, Vincent HH, Yzerman EPF, Vogel M, Mouton JW: Drug cleared by continuous hemodiafiltration (CAVHD): results with the AN69 capillary hemofilter and recommended dose adjustments for seven antibiotics. Drug Invest 1994. In press
Tillement JP, Lhoste F, Findicelli TF: Diseases and drug protein binding. Clin Pharmacokinet 3: 144, 1978
Lee CS, Marbury TC: Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetical considerations. Clin Pharmacokinet 9: 42, 1984
Piafsky KM: Disease induced changes in the serum binding of basic drugs. Clin Pharmacokinet 5: 246, 1980
Garfinkel D, Mamelok RD, Blaschke TF: Altered therapeutic range for quinidine after myocardial infarction an cardiac surgery. Ann Intern Med 107: 48, 1987
Reidenberg MM: The biotransformation of drugs in renal failure. Am J Med 62: 482, 1977
Aronoff GR, Luft FC: Antimicrobial therapy in patients with impaired renal function. Dial Transplant 8: 14, 1979
Bennett WM, Hartnett MN, Craven R, Gilbert DN, Porter GA: Gentamicin concentrations in blood, urine and renal tissue of patients with end-stage renal disease. J Lab Clin Med 90: 389, 1977
Bennett WM, Craven R: Urinary tract infections in patients with severe renal disease: treatment with ampicillin and trimethoprim-sulfamethoxazole. JAMA 236: 946, 1976
Elzinga L, Golper TA, Rashad AL, Carr ME, Bennett WM: Trimethoprim-sulfamethoxazole activity in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 32: 884, 1987
Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM: Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 32: 844, 1988
Miller RD, Cullen DJ: Renal failure and post-operative respiratory failure: recurarization? Br J Anaesth 48: 253, 1976
Phillips ME, Eastwood JB, Curtis JR, Gower PC, De Wardener HE: Tetracycline poisoning in renal failure, Br Med J 2(911): 149, 1974
Al-Damluji S, Meek JH: Interference of a propranolol metabolite with serum bilirubin estimation in chronic renal failure. Br Med J 280(6229): 1414, 1980
Molitch ME, Rodman E, Hirsch CA, Dubinsky E: Spurious serum creatinine elevations in ketoacidosis. Ann Inter Med 93:280, 1980
Baba S, Baba T, Iwanga T: Effect of acetohexamide (a sulfonylurea hypoglycemic agent) in blood plasma on creatinine assay in clinical laboratory tests. Chem Pharmacol Bull 27: 139, 1979
Maddocks J, Hann S, Hopkins M, Coles GA: The effect of methyldopa on creatinine estimation. Lancet 1(795): 157, 1973
Ayneck ML, Berardi RR, Johnson RM: Interference of cephalosporins and cefoxitin with serum creatinine determination. Am J Hosp Pharm 38: 1348, 1981
Burgess E, Blair A, Krichman K, Cutler RE: Inhibition of renal creatinine secretion by cimetidine in humans. Renal Physiol 5: 27, 1982
Rainer G, Rosenberg AR: Effect of co-trimoxazole on the glomerular filtration rate of healthy adults. Chemotherapy 27: 229, 1981
Vincent HH, Vos MC, Akcahuseyin E, Goessens WHF, van Duyl WA, Schalekamp MADH: Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif 11: 99, 1993
Keller F, Wilms H, Schultze G, Offerman G, Molzahn M: Effect of plasma protein binding, volume of distribution, and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 19: 201, 1983
Maher JF: Pharmacokinetics in patients with renal failure. Clin Nephrol 21: 39, 1984
Dromgoole SH: The effect of hemodialysis on the binding capacity of albumin. Clinica Chim Acta 46: 269, 1973
Rutstein DD, Castelli WP, Nickerson, R: Heparin and human lipid metabolism. Lancet 1(603): 1003, 1969
Suh B, Craig WA, England AC, Elliott RL: Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis 143:609, 1981
Golper TA, Saad AM: Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Kidney Int 30: 937, 1986
Fabris A, La Greca G, Chiaramonte S et al.: Total solute extraction versus clearance in the evaluation of standard and short hemodialysis. Trans Am Soc Artif Intern Organs 34: 627, 1988
Sprenger KGB, Stephan H, Kratz W, Huber K, Franz HE: Optimizing of hemodiafiltration with modern membranes? Contrib Nephrol 46: 43, 1985
De Bock V, Verbeelen D, Maes V, Sennesael J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis and hemofiltration. Nephrol Dial Transplant 4: 635, 1989
Matzke GR, O’Connell MB, Collins AJ, Keshaviah PR: Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 40: 425, 1986
Marbury TC, Lee CS, Perchalski RJ, Wilder BJ: Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 38: 1757, 1981
Lee CS, Marbury TC, Benet LZ: Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm 8: 69, 1980
Levy G: Pharmacokinetics in renal disease. Am J Med 62: 461, 1977
Gibson TP: Problems in designing hemodialysis drug studies. Pharmacotherapy 5: 23, 1985
Brunner H, Mann H, Stiller S, Sieberth HG: Permeability for middle and higher molecular weight substances. Contrib Nephrol 46: 33, 1985
Donahue PR, Ahmad S: Dialyzer permeability alteration by reuse. (Abstract) J Am Soc Nephrol 3: 363, 1992
Graeber CW, Halley SE, Lapkin RA, Kaplan AA: Protein losses with reused dialyzers. (Abstract) J Am Soc Nephrol 4: 349, 1993
Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 35: 1409, 1989
Bastani R, Spyker DA, Minocha A, Cummings R, Westervelt FB Jr: In vivo comparison of three different hemodialysis membranes for vancomycin clearance: cuprophan, cellulose acetate, and polyacrylonitrile. Dial Transpl 17: 527, 1988
Barth RH, DeVincenzo N, Zara AC, Berlyne GM: Vancomycin pharmacokinetics in high-flux hemodialysis. (Abstract) J Am Soc Nephrol 1: 348, 1990
Agarwal R, Toto RD: Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. Am J Kidney Dis 22: 296, 1993
Jindal K, McDougall J, Goldstein M: High flux dialyzers: impact of ultrafiltration and surface area on clearance of small and large molecular weight substances. (Abstract) Nat Kidney Found p A10, 1987
Von Albertini B, Miller JH, Gardner PW, Shinaberger JH: Performance characteristics of high flux haemodiafiltration. Proc Eur Dial Transplant Assoc 21: 447, 1984
Surian M, Malberti F, Corradi B et al.: Adequacy of haemodiafiltration. Nephrol Dial Transplant 4: 32, 1989
Rumpf KW, Rieger J, Doht B, Ansorg R, Scheler F: Drug elimination by hemofiltration. J Dialysis 1: 677, 1977
Ernest D, Cutler DJ: Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med 20: 586, 1992
Rumpf KW, Rieger J, Ansorg R et al.: Binding of antibiotics by dialysis membranes and its clinical relevance. Proc Eur Dial Transpl Assoc 14: 607, 1978
Kraft D, Lode H: Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 57: 195, 1979
Kronfol NO, Lau AH, Barakat MM: Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. Trans Am Soc Artif Intern Organs 33: 300, 1987
Kronfol N, Lau AH, Colon-Rivera J, Libertin CL; Effect of CAVH membrane types on drug sieving coefficients and clearances. Trans Am Soc Artif Intern Organs 32: 85, 1986
Lau AH, Kronfol NO, Jaber N, Libertin CL: Determinants of drug removal by continuous arteriovenous hemofiltration. (Abstract) Drug Intell Clin Pharm 20: 467, 1986
Kronfol N, Lau A, Jaber N, Libertin CL: Effect of membrane properties on drug clearances by CAVH. (Abstract) Nat Kidney Found A10, 1986
Henderson LW: Hemodialysis: rationale and physical principles, in The Kidney, 1st Edition, edited by Brenner BM, Rector FC, Philadelphia, WB Sanders Company, 1976, p 1643
Husted FC, Nolph KD, Vitale FC, Maher JF: Detrimental effects of ultrafiltration on diffusion in coils. J Lab Clin Med 87: 435, 1976
Nolph KD, New DL: Effects of ultrafiltration on solute clearances in hollow fiber artificial kidneys. J Lab Clin Med 88:593, 1976
Nolph KD, Hopkins C, Van Stone J: Effects of ultrafiltration on solute clearances in parallel plate dialyzars. Clin Nephrol 8: 453, 1977
Henderson LW, Silverstein ME, Ford CA, Lysaght MJ: Clinical response to maintenance hemodiafiltration. Kidney Int (Suppl 2): S58, 1975
Hamilton R, Ford C, Colton C, Cross R, Steinmuller S, Henderson L: Blood cleansing by diafiltration in uremic dog and man. Trans Am Soc Artif Intern Organs 17: 259, 1971
Henderson LW, Ford C, Colton CK, Bluemle LW, Bixler HJ: Uremic blood cleansing by diafiltration using hollow-fiber ultrafilter. Trans Am Soc Artif Intern Organs 16: 107. 1970
Jaffrin MY, Ding L, Laurent JM: Simultaneous convective and diffusive mass transfers in a hemodialyzer. J Biomech Eng 112: 212, 1990
Vincent HH, van Ittersum FJ, Akcahuseyin E, Vos MC, Van Duyl WA, Schalekamp MA: Solute transport in continuous arteriovenous hemodiafiltration: a new mathematical model applied to clinical data. Blood Purif 8: 9, 1990
Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 36: 35, 1991
Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow fiber blood ultrafilter. J Lab Clin Med 85: 355, 1975
Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST. Paganini EP: Drug removal during CAVH: theory and clinical observations. Intern J Artif Organs 8: 307, 1985
Ronco C, Brendolan A, Borin D et al.: Permeability characteristics of polysulfonic membranes in CAVH, in Continuous Arteriovenous Hemofiltration (CAVH), edited by Sieberth HG, Mann H, Basel, Karger, 1985, p 59
Frigon RP, Leypoldt JK, Alford MF, Uyeji S, Henderson LW: Hemofilter solute sieving is not governed by dynamically polarized protein. Trans Am Soc Artif Intern Organs 30: 486, 1984
Lysaght MJ: An experimental model for the ultrafiltration of sodium ion from blood or plasma. Blood Purif 1: 25, 1983
Leypoldt JK, Frigon RP, Henderson LW: Macromolecular charge affects hemofilter solute sieving. Trans Am Soc Artif Intern Organs 32: 384, 1986
Kaplan AA, Longnecker RE, Folkert VW: Continuous arteriovenous hemofiltration — a report of 6 months’ experience. Ann Intern Med 100: 358, 1984
Paganini EP, Flague J, Whitman G, Nakamoto S: Amino acid balance in patients with oliguric renal failure undergoing slow continuous ultrafiltration (SCUF). Trans Am Soc Artif Intern Organs 28: 615, 1982
Golper TA, Vincent HH, Kroh U: Drug use in critically ill patients with acute renal failure, in Acute Renal Failure in the Critically III, edited by Bellomo R, Ronco C, Heidelberg, Springer-Verlag, 1995. In press
Kroh U, Hofmann W, Dehne M, el Abed K, Lennartz H: Dosisanpassung von pharmaka während kontinuierlicher hämofiltration. Anaesthesist 38: 225, 1989
Leypoldt JK, Frigon RP, Henderson LW: Dextran sieving coefficients of hemofilter membranes. Trans Am Soc Artif Intern Organs 29: 678, 1983
Dodd NJ, O’Donovan RM, Bennett-Jones DN et al.: Arteriovenous hemofiltration: a recent advance in the management of renal failure. Br Med J 287: 1008, 1983
Bennett WM, Aronoff GR, Golper TA, Morrison G, Brater DC, Singer I: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 3rd Edition. Philadelphia, American College of Physicians, 1994
Keller E, Reetze P, Schollmeyer P: Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 18: 104, 1990
Golper TA: Drugs and peritoneal dialysis. Dial Transplant 8:41, 1979
Lasrich M, Maher JM, Hirszel P, Maher JF: Correlation of peritoneal transport rates with molecular weight: a method for predicting clearances. ASAIO J 2: 107, 1979
Nolph KD, Popovich RP, Ghods AS, Twardowski Z: Determinants of low clearances of small solutes during peritoneal dialysis. Kidney Int 13: 117, 1978
Robson M, Oreopoulos DG, Izatt S, Olivie R, Rapaport R, de Veber GA: Influence of exchange volume and dialysate flow rate on solute clearance in peritoneal dialysis. Kidney Int 14: 486, 1978
Zelman A, Gisser D, Whitlam PJ, Parsons RH, Shuyler R: Augmentation of peritoneal dialysis efficiency with programmed hyper/hypoosmotic dialysates. Trans Am Soc Artif Intern Organs 23: 203, 1977
Rubin J, Adair C, Barnes T, Bower J: Dialysate flow rate and peritoneal clearance. Am J Kidney Dis 4: 260, 1984
Gross M, McDonald HP: Effect of dialysate temperature and flow rate on peritoneal clearance. JAMA 202: 363, 1967
Indraprasit S, Namwongprom A, Sooksriwongse C, Buri PS: Effect of dialysate temperature on peritoneal clearances. Nephron 34: 45, 1983
Manuel MA, Paton TW, Cornish WR: Drugs and peritoneal dialysis. Perit Dial Bull 3: 117, 1983
Janknegt R, Koks CH: Pharmacologic aspects during continuous ambulatory peritoneal dialysis: a literature review. Pharmaceutisch Weekblad 6: 229, 1984
Paton TW, Cornish WR, Manuel MA, Hardy BG: Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 10: 404, 1985
Smithivas T, Hyams PJ, Matalon R, Simberkoff MS, Rahal JJ Jr: The use of gentamicin in peritoneal dialysis. I. Pharmacologic results. J Infect Dis 124(Suppl): S77, 1971
Singlas E, Colin JN, Rottenbourg J et al.: Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. Eur J Clin Pharmacol 21: 409, 1982
Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33: 66, 1983
Roscoe JM: Practices of insulin administration in CAPD. Perit Dial Bull 2(Suppl 2): S27, 1982
Furman KI, Gomperts ED, Hockley J: Activity of intraperitoneal heparin during peritoneal dialysis. Clin Nephrol 9: 15, 1978
Golper TA, Bennett WM, Jones SR: Peritonitis associated with chronic peritoneal dialysis: a diagnostic and therapeutic approach. Dial Transplant 7: 282, 1978
Millikin SP, Matzke GR, Keane WF: Antimicrobial treatment of peritonitis associated with continuous ambulator peritoneal dialysis. Perit Dial Int 11: 252, 1991
Sewell DL, Golper TA, Brown SD, Nelson E, Knower M, Kimbrough RC: Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 3: 209, 1983
Blaser J, Rüttimann S, Bhend H, Luthy R: Increase of amikacin half-life during therapy in patients with renal insufficiency. Antimicrob Agents Chemother 23: 888, 1983
Lanao JM, Dominguez-Gil A, Tabemero JM, Sanchez Tomero JA: Pharmacokinetics of amikacin (BB-K8) in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17: 357, 1979
Smeltzer BD, Schwartzman MS, Bertino JS: Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 32: 236, 1988
Goetz DR, Pancorbo S, Hoag S, Bloom P: Prediction of serum gentamicin concentrations in patients undergoing hemodialysis. Am J Hosp Pharm 37: 1077, 1980
Gyselynck AM, Forrey A, Cutler R: Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis 124(Suppl): S70, 1971
Zarowitz BJ, Anandan JV, Dumler F et al.: Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol 26: 686, 1986
Healy JK, Drum PJ, Elliott AJ: Kanamycin dosage in renal failure. Aust N Z J Med 3: 474, 1973
Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL: Netilmicin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 38: 703, 1989
Herrero A, Rius Alarcó F, García Díez JM, Mahiques E, Domingo JV: Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis. Int J Clin Pharmacol Ther Toxicol 26: 84, 1988
Pechére JC, Dugal R, Pechére MM: Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis. Clin Pharmacokinet 3: 395, 1978
Seyffart G (ed): Drug Dosage in Renal Insufficiency, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1991
Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166, 1976
Pechere JC, Dugal R: Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. J Infect Dis 134(Suppl): S118, 1976
Wise R: The pharmacokinetics of the oral cephalosporins — a review. J Antimicrob Chemother 26(Suppl E): 13, 1990
Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E: Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis. J Antimicrob Chemother 5: 465, 1979
Leroy A, Humbert G, Godin M: Pharmacokinetics of cefadroxil in patients with impaired renal function. J Antimicrob Chemother 10(Suppl B): 39, 1982
Bliss M, Mayersohn M, Arnold T, Logan J, Michael UF, Jones W: Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 29: 649, 1986
Brogard JM, Kopferschmitt J, Spach MO, Grudet O, Lavillaureix J: Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 19: 366, 1979
Bergan T, Brodwall EK, Ørjavik Ø: Pharmacokinetics of cefazolin in patients with normal and impaired renal function. J Antimicrob Chemother 3: 453, 1977
Guay DRP, Meatherall RC, Harding GK, Brown GR: Pharmacokinetics of cefixime (CL 284,635; FK027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 30: 458, 1986
Campoli-Richards DM, Todd PA: Cefmenoxime. A review of its antibacterial activity pharmacokinetic properties and therapeutic use. Drugs 34: 188, 1987
Evers J, Borner K, Koeppe P: Elimination of cefmenoxime during continuous haemofiltration. Eur J Clin Pharmacol 44(Suppl 1): S31, 1993
Konishi K: Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother 30: 901, 1986
Halstenson CE, Guay DR, Opsahl JA et al.: Disposition of cefmetazole in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother 34:519, 1990
Schentag JJ: Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy 11:2, 1991
Blair AD, Maxwell BM, Forland SC, Jacob L, Cutler RE: Cefonicid kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 35: 798, 1984
Saltiel E, Brogden RN: Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 32: 222, 1986
Greenfield RA, Gerber AU, Craig WA: Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis 5(Suppl): S 127, 1983
Hodler JE, Galeazzi RL, Frey B, Rudhardt M, Seiler AJ: Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications. Eur J Clin Pharmacol 26: 609, 1984
Campoli-Richards DM, Lackner TE, Monk JP: Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 34: 411, 1987
Hess JR, Berman SJ, Boughton WH et al.: Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrob Agents Chemother 17: 251, 1980
Matzke GR, Abraham PA, Halstenson CE, Keane WF: Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 38: 31, 1985
Todd PA, Brogden RN: Cefotaxime. An update of its pharmacology and therapeutic use. Drugs 40: 608, 1990
Ohkawa M, Hirano S, Tokunaga S: Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother 23: 31, 1983
Ward A, Richards DM: Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 382, 1985
Greaves WL, Kreeft JH, Ogilvie RI, Richards GK: Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother 19: 253, 1981
Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C: Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis 1: 118, 1979
Nikolaidis P, Tourkantonis A: Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 24: 142, 1985
Richards DM, Brogden RN: Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 105, 1985
Tourkantonis A, Nicolaidis P: Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother 12(Suppl A): 263, 1983
Welage LS, Schultz RW, Schentag JJ: Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 25: 201, 1984
Burgess ED, Blair AD: Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 24: 237, 1983
Gross ML, Somani P, Ribner BS, Roeader R, Freimer EH, Higgins JT Jr: Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34: 673, 1983
Kowalsky SF, Echols RM, Venezia AR, Andrews EA: Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function. Antimicrob Agents Chemother 24: 151, 1983
Richards DM, Heel RC: Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 281, 1985
Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ: Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25: 438, 1984
Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agent Chemother 25: 83, 1984
Yuk JH, Nightingale CH, Quintiliani R: Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet 17: 223, 1989
Höffler D, Koeppe P, Schleith A: Pharmacokinetics of cefuroxime-axetil in patients undergoing haemodialysis therapy. Acta Therapeutica 17: 107, 1991
Konishi K, Suzuki H, Hayashi M, Saruta T: Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother 31: 413, 1993
Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B: Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 30: 282, 1988
Bailey RR, Gower PE, Dash CH: The effects of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. Postgrad Med J 46(Suppl): 60, 1970
Venuto RC, Plaut M: Cephalothin handling in patients undergoing hemodialysis. Antimicrob Agents Chemother 10: 50, 1970
McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF: Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrob Agents Chemother 1: 90, 1972
Solomon AE, Briggs JD: The administration of cephradine to patients in renal failure. Br J Clin Pharmacol 2: 443, 1975
Bolton WK, Scheld WM, Spyker DA, Overby TL, Sande MA: Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother 18:933, 1980
Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, Avery GS: Moxalactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. drugs 26: 279, 1983
Srinivasan S, Neu HC: Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis. Antimicrob Agents Chemother 20: 398, 1981
Cooper MA, Nye K, Andrews JM, Wise R: The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 26: 533, 1990
Foulds G, Shephard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A): 73, 1990
Peters DH, Clissold SP: Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44: 117, 1992
Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A: Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int J Clin Pharmacol Ther Toxicol 24: 460, 1986
Kanfer A, Stamatakis G, Torlotin C, Fredj G, Kenouch S, Mery JP: Changes in erythromycin pharmacokinetic induced by renal failure. Clin Nephrol 27: 247, 1987
Francke EL, Appel GB, Neu HC: Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin Pharmacol Ther 26: 3, 1979
Humbert G, Spyker DA, Fillastre JP, Leroy A: Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 15: 28, 1979
Todd PA, Benfield P: Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39: 264, 1990
Blum RA, Kohli RK, Harrison NJ, Schentag JJ: Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 33: 1470, 1989
Leroy A, Humbert G, Godin M, Fillastre JP: Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Antimicrob Agents Chemother 17: 344, 1980
Whelton A, Stout RL, Delgado FA: Azlocillin kinetics during extracorporeal haemodialysis and peritoneal dialysis. J Antimicrob Chemother 11(Suppl B): 89, 1983
Aronoff GR, Sloan RS, Luft FC, Nelson RL, Maxwell DR, Kleit SA: Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther 28: 523, 1980
Kampf D, Schurig R, Weihermüller K, Forester D: Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrob Agents Chemother 18: 81, 1980
Baron DN, Hamilton-Miller JM, Brumfitt W: Sodium content of injectable β-Lactam antibiotics. Lancet i(8386): 1113, 1984
Holmes B, Richards DM, Brogden RN, Heel RC: Piperacillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 28: 375, 1984
De Schepper PJ, Tjandramage RB, Mullie A et al.: Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother 9Suppl B): 1982
Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO: Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother 23: 881, 1983
Parry MF, Neu HC: Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis 133: 46, 1976
Vance-Bryan K, Guay DR, Rotschafer JC: Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 19: 434, 1990
Davies SP, Azadian BS, Kox WJ, Brown EA: Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant 7: 848, 1992
Kowalsky SF, Echols M, Schwartz MT, Baile GR, McCCormick E: Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol 39: 53, 1993
Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14: 96, 1988
Henwood JM, Monk JP: Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 36: 32, 1988
Nix DE, Schultz RW, Frost RW et al.: The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother 21(Suppl B): 87, 1988
Weidekamm E: Pharmacokinetics of fleroxacin in renal impairment. Am J Med 94: 70S, 1993
Holmes B, Brogden RN, Richards DM: Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 482, 1985
Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S: Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin Pharmacokinet 21: 357, 1991
Saivin S, Houin G: Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15: 355, 1988
Siegel D: Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects. N Y State J Med 78: 950, 1978
Fillastre JP, Leroy A, Baudoin C et al.: Pharmacokinetics of aztreonam in patients with chronic renal failure. Clin Pharmacokinet 10: 91, 1985
Gerig JS, Bolton ND, Swabb EA, Scheid WM, Bolton WK: Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int 26: 308, 1984
Ambrose PJ: Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 9: 222, 1984
Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/Cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44: 408, 1992
Gibson TP, Devetriades JL, Bland JA: Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 78(Suppl 6A): 54, 1985
Konishi K, Suzuki H, Saruta T et al.: Removal of imipenem and cilastatin by hemodialysis in patients with end stage renal failure. Antimicrob Agents Chemother 35: 1616, 1991
Vos MC, Vincent HH, Yzerman EP: Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med 18:282, 1992
Roberts AP, Eastwood JB, Gower PE, Fenton C, Curtis J: Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol 14: 435, 1978
Guay DR, Meatherall RC, Baxter H, Jacyk WR, Penner B: Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 25: 306, 1984
Kreeft JH, Ogilvie RI, Dufresne LR: Metronidazole kinetics in dialysis patients. Surgery 93: 149, 1983
Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danzinger LH: Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23: 328, 1992
Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S: Pharmacokinetics of sulfisoxazole in renal transplant patients. Antimicrob Agents Chemother 28: 535, 1985
Bonati M, Traina GL, Villa G et al.: Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet 12: 292, 1987
Campoli-Richards DM, Brogden RN, Faulds D: Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40: 449, 1990
Paap CM, Nahata MC: Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP, Ann Pharmacother 23: 646, 1989
Moellering RC, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function; a nomogram for dosage. Ann Intern Med 94: 343, 1981
Nielsen HE, Sorensen I, Hansen HE: Peritoneal transport of vancomycin during peritoneal dialysis. Nephron 24: 274, 1979
Daneshmend TK, Warnock DW: Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 8: 17, 1983
Lyman CA, Walsh TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44: 9, 1992
Craven PC, Ludden TM, Drutz DJ, Rogers W, Haegele KA, Skrdlant HB: Excretion pathways of amphotericin B. J Infect Dis 140: 329, 1979
Morgan DJ, Ching MS, Raymond K et al.: Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 34: 248, 1983
Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ: Liposomal and lipid formulations amphotericin B. Clin Pharmacokinet 23: 279, 1992
Cleary JD, Taylor JW, Chapman SW: Imidazoles and triazoles in antifungal therapy. Ann Pharmacother 26: 502, 1992
Bailey EM, Krakovsky DJ, Rybak MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10: 146, 1990
Toon S, Ross CE, Gokal R, Rowand M: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 29: 221, 1990
Oono S, Tabei K, Tetsuka T, Asano Y: The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol 42: 667, 1992
Debruyne D, Ryckelynck JP: Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 24: 10, 1993
Bennet JE: Flucytosine. Ann Intern Med 86: 319, 1977
Cutler RE, Blair AD, Kelly MR: Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 24: 333, 1978
Eisenberg ES: Intraperitoneal flucytosine in the management of fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 11: 465, 1988
Boelaert J, Schurgers M, Matthys E et al.: Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 32: 1595, 1988
Grant SM, Clissold SP: Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310, 1989
Daneshmend TK, Warnock DW: Clinical pharmacokinetics of ketoconazole. Clin Pharmacokin 14: 13, 1988
Lewi PJ, Boelaert J, Daneels R et al.: Pharmacokinetic profile of intravenous miconazole in man. Eur J Clin Pharmacol 10: 49, 1976
White NJ: Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 187, 1985
White NJ: Antimalarial pharmacokinetics and treatment regimens. BrJ Clin Pharmacol 34: 1, 1992
Edwards G, Breckenridge AM: Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 15: 67, 1988
Keystone JS, Murdoch JK: Mebendazole. Ann Intern Med 91:582, 1979
Palmer KJ, Holliday SM, Brogden RN: Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45: 430, 1993
Goa KL, Compoli-Richards DM: Pentamidine Isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242, 1987
Conte JE Jr: Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 163: 169, 1991
King CH, Mahmoud AA: Drugs five years later: praziquantel. Ann Intern Med 110: 290, 1989
Lehmann CR, Garrett LE, Winn RE et al.: Capreomycin kinetics in renal impairment and clearance by hemodialysis. Ann Rev Respir Dis 138: 1312, 1988
Varughese A, Brater DC, Benet LZ, Lee CS: Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis 134: 34, 1986
Weber WW, Hein DW: Clinical pharmacokinetics of iso-niazid. Clin Pharmacokinet 4: 401, 1979
Lacroix C, Hermelin A, Guiberteau R et al.: Haemodialysis of pyrazinamide in uraemic patients. Eur J Clin Pharmacol 37: 309, 1989
Stamatikis G, Montes C, Trouvin JH et al.: Pyrazinamide and pyrazinoic acid pharmacokinetics inpatients with chronic renal failure. Clin Nephrol 30: 230, 1988
Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3: 108, 1978
Burgess ED, Gill MJ: Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. J Clin Pharmacol 30: 997, 1990
Laskin OL, Longstreth JA, Whelton A et al.: Acyclovir kinetics in end-stage renal disease. Clin Pharmacol Ther 31:594: 1982
O’Brien JJ, Campoli-Richards DM: Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37: 233, 1989
Aoki FY, Sitar DS: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14: 35, 1988
Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK: Pharmacokinetics amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94: 454, 1981
Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC: Amantadine hydrochloride pharmacokinetics patients with impaired renal function. Clin Nephrol 17: 19, 1982
Morse GD, Shelton MJ, O’Donnell AM: Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 24: 101, 1993
Faulds D, Brogden RN: Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44: 94, 1992
Chrisp P, Clissold SP: Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41: 104, 1991
Faulds D, Heel RC: Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39: 597, 1990
Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD: Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 34: 489, 1990
Aronoff GR, Szwed JJ, Nelson RL, Marcus RL, Kleit SA: Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrob Agents Chemother 18: 212, 1980
Collins JM, Unadkat JD: Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 17: 1, 1989
Gallicano KD, Tobe S, Saha J et al.: Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J Acquir Immune Defic Syndr 5: 242, 1992
Garraffo R, Cassuto-Viguier E, Barillon J, Changlet L, Lapalus P, Duplay H: Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports. Int J Clin Pharmacol Ther Toxicol 27: 535, 1989
Gleason JR, Brier ME: Zidovudine in renal failure. Semin Dial 3: 101, 1990
Chan GL, Matzke GR: Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 21: 773, 1987
Horton MW, Byerly WG: Opioid analgesics. Semin Dial 3: 187, 1990
Heel RC, Brogden RN, Speight TM, Avery GS: Butorphanol: a review of its pharmacological properties and therapeutic efficacy. Drugs 16: 473, 1978
Barnes JN, Williams AJ, Tomson MJ, Toseland PA, Goodwin PJ: Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J 290(6470)L 740, 1985
Mather LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 8: 422, 1983
Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J. Reidenberg MM: Accumulation of normeperidine, and active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86: 738, 1977
Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 5: 197, 1980
Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P: Morphine pharmacokinetics in renal failure. Anesthesiology 66: 327, 1987
Säwe J, Odar-Cederlöf I: Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 32: 377, 1987
Giacomini KM, Gibson TP, Levy G: Effect of hemodialysis on propoxyphene and norpropoxyphenne concentrations in blood of anephric patients. Clin Pharmacol Ther 27: 508, 1980
Clissold SP: Paracetamol and phenacetin. Drugs 32(Suppl 4): 46, 1986
Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ: Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36: 291, 1989
Needs CJ, Brooks PM: Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10: 164, 1985
Agoston S, Vandenbrom RH, Wierda JM: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 22: 94, 1992
Davis PJ, Cook DR: Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 11: 18, 1986
Pollard BJ: Editorial: neuromuscular blocking drugs and renal failure. Br J Anaesth 68: 545, 1992
Gramstad L: Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine. Br J Anaesth 59: 995, 1987
Mongin-Long D, Chabrol B, Baude C et al.: Atracurium in patients with renal failure. Clinical trial of a new neuromuscular blocker. Br J Anaesth 58(Suppl): 44S, 1986
Ramzan MI, Shanks CA, Triggs EJ: Gallamine disposition in surgical patients with chronic renal failure. J Clin Pharmacol 12: 141, 1981
Brotherton WP, Matteo RS: Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. Anesthesiology 55: 273, 1981
Aquilonius SM, Hartvig P: Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet 11: 236, 1986
McLeod K, Watson MJ, Rawlins MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48: 341, 1976
Kirvela M, Olkkola KT, Rosenberg PH, Yli-Hankala A, Salmela K, Lingren L: Pharmacokineties of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. Br J Anaesth 68: 178, 1992
Cronnelly R, Stanski DR, Miller RD, Sheiner LB: Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther 28: 78, 1980
Bishop M, Hornbein TF: Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology 58: 384, 1983
Matteo RS. Nishitateno K, Pua EK, Spector S: Pharmacokinetics of d-tubocurarine in man: effect of an osmotic diuretic on urinary excretion. Anesthesiology 52: 335, 1980
Lynam DP, Cronnelly R, Castagnoli KP et al.: The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 69: 227, 1988
Hulter HN, Licht JH, Ilnicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency. J Lab Clin Med 94: 223, 1979
Lowenthal DT, Matzek KM, MacGregor TR: Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 14: 287, 1988
Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR: Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 40: 561, 1986
Young RA, Brogden RN: Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 35: 525, 1988
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS: Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26: 212, 1983
Finnerty FA, Brogden RN: Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 30: 22. 1985
Halstenson CE, Opsahl JA, Abraham PA et al.: Disposition of guanadrel in subjects with normal and impaired renal function. J Clin Pharmacol 29: 128, 1989
Carchman SH, Sica DA, Davis J et al.: Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency. Nephron 53: 18, 1989
Sorkin EM, Heel RC: Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31:301, 1986
Myhre E, Rugstad HE, Hansen T: Clinical pharmacokinetics of methyldopa. Clin Pharmacokinet 7: 221, 1982
Lameire N, Gordts J: A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. Eur J Clin Pharmacol 31: 333, 1986
Vincent J, Meredith PA, Reid JL, Elliot HL, Rubin PC: Clinical pharmacokinetics of prazosin — 1985. Clin Pharmacokinet 10: 144, 1985
Zsoter TT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14: 325, 1973
Jungers P, Ganeval D, Pertuiset N, Chaveau P: Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am J Med 80(Suppl 5B): 94, 1986
Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 24: 230, 1993
Balfour JA, Goa KL: Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 42: 511, 1991
Brogden RN, Todd PA, Sorkin EM: Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540, 1988
Duchin KL, Pierides AM, Heald A, Signhvl HM, Rommel AAJ: Elimination kinetics of captopril in patients with renal failure. Kidney Int 25: 942, 1984
Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y: Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron 44: 324, 1986
Fruncillo RJ, Rocci ML Jr, Vlasses PH et al.: Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 31(Suppl 20): S117, 1987
Todd PA, Goa KL: Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43: 346, 1992
Gehr TW, Sica DA, Grasela DM, Fakhry I, Davis J, Duchin KL: Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 41: 165, 1991
Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N: Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457, 1991
Murdoch D, McTavish D: Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 43: 123, 1992
Lancaster SG, Todd PA: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646, 1988
van Schaik BA, Geyskes GG, van der Wouw PA, van Rooij HH, Porsius AJ: Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol 34: 61, 1988
Halstenson CE, Opsahl JA, Rachael K et al.: The pharma-cokinetics of quinapril and its active metabolite quinaprilat in patients with varying degrees Rnal function. J Clin Pharmacol 32: 344, 1992
Schunkert H, Kindler J, Gassmann M et al.: Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol 37: 249, 1989
Todd PA, Benfield P: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110, 1990
Gill J, Heel RC, Fitton A: Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43: 69, 1992
Josselson J, Narang PK, Adir J, Yacobi A, Sadler JH: Bretylium kinetics in renal insufficiency. Clin Pharmacol Ther 33: 144, 1983
Rapeport WG: Clinical pharmacokinetics of bretylium. Clin Pharmacokinet 10: 248, 1985
Brogden RN, Todd PA: Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs 34: 151, 1986
Burk M, Peters U: Disopyramide kinetics in renal impairment: determinants of interindividual variability. Clin Pharmacol Ther 34: 331, 1983
Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE: Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 5: 35, 1985
Bergstrand RH, Wang T, Roden DM et al.: Encainide disposition in patients with renal failure. Clin Pharmacol Ther 40: 64, 1986
Brogden RN, Todd PA: Encainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 34:519, 1987
Forland SC, Burgess E, Blair AD et al.: Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol 28: 259, 1988
Forland SC, Cutler RE, McQuinn RL et al.: Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 28: 727, 1988
Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M: Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokinet Biopharm 10: 265, 1982
Eiriksson CE, Brogden RN: Lorcainide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 279, 1984
Monk JP, Brogden RN: Mexiletine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40: 374, 1990
Wang T, Wuellner D, Woosley RL, Stone WJ: Pharmacokinetics and nondialyzability of mexiletine in renal failure. Clin Pharmacol Ther 37: 649, 1988
Fitton A, Buckley MT: Moricizine: a review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Drugs 40: 138, 1990
Pieniaszek HJ, McEntegart CM, Mayersohn M, Michael UF: Moricizine pharmacokinetics in renal insufficiency: reevaluation of elimination half-life. J Clin Pharmacol 32: 412, 1992
Stec GP, Atkinson AJ, Nevin MJ et al.: N-actylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 26: 618, 1979
Harron DW, Brogden RN: Acecainide (N-acetylprocainamide): a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs 39: 720, 1990
Raehl CL, Moorthy AV, Beirne GJ: Procainamide pharmacokinetics in patients on continuous ambulatory’ peritoneal dialysis. Nephron 44: 191, 1986
Bryson HM, Palmer KJ, Langtry HD, Fitton A: Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 45: 85, 1993
Burgess E, Duff H, Wilkes P: Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol 29: 112, 1989
Crevasse L: Quinidine: an update on therapeutics, pharmacokinetics and serum concentration monitoring. Am J Cardiol 62: 221, 1988
Kessler KM, Perez GO: Decreased quinidine plasma protein binding during hemodialysis. Clin Pharmacol Ther 30: 121, 1981
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS: Tocainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 26: 93, 1983
Rachl CL, Beirne GJ, Moorthy AV, Patel AK: Tocainide pharmacokinetics during continuous ambulatory peritoneal dialysis. Am J Cardiol 60: 747, 1987
Wiegers U, Hanrath P, Kuck KH et al.: Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. Eur J Clin Pharmacol 24: 503, 1983
Borehard U: Pharmacokineties of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 8(Suppl 2): 28, 1990
Riddell JG, Harron DW, Shanks RG: Clinical pharmacokinetics of β-adrenoceptor antagonists. An update. Clin Pharmacokinet 12: 305, 1987
Kirch W, Köhler H, Berggren G, Braun W: The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetylmetabolite. ClinNephrol 18: 88, 1982
Roux A, Aubert P, Guedon J, Flouvat B: Pharmacokineties of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol 17: 339, 1980
Singh BN, Thoden WR, Ward A: Acebutolol: a review of pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs 29: 531, 1985
Kirch W, Kohler H, Mutschler E, Schafer M: Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19: 65, 1981
Wadworth A, Murdoch D, Brogden RN: Atenolol: a reappraisal of its pharmacological properties, and therapeutic use in cardiovascular disorders. Drugs 42: 468, 1991
Beresford R, Heel RC: Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. drugs 31: 6, 1986
Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y: Pharmacokinetics of carteolol in patients with impaired renal function. Eur J Clin Pharmacol 43: 417, 1992
Hasenfub G, Schafer-Korting M, Knauf H, Mutschler E, Just H: Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol 29: 461, 1985
Chrisp P, Goa KL: Dilevalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension. Drugs 30: 234, 1990
Kelly JG, Laher MS, Donohue J, Doyle GD: The pharmacokinetics of dilevalol in renal impairment. J Hum Hypertens 4(Suppl 2): 59, 1990
Benfield P, Sorkin EM: Esmolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 33: 392, 1987
Flaherty JF, Wong B, LaFollette G, Warnock DG, Hulse JD, Gambertoglio JG: Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther 45: 321, 1989
Goa KL, Benfield P, Sorkin EM: Labetalol: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischemic heart disease. Drugs 37: 583, 1989
Halstenson CE, Opsahl JA, Pence TV et al.: The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther 40: 462, 1986
Regardh CG, Johnsson G: Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5: 557, 1980
Dreyfuss J, Griffith DL, Singhvi SM et al.: Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single-and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol 19: 712, 1979
Frishman WH: Nadolol: a new B-adrenoceptor antagonist. N Engl J Med 305: 678, 1981
Bernard N, Cuisinaud G, Pozet N, Zech PY, Sassard J: Pharmacokinetics of penbutolol and its metabolites in renal insufficiency. Eur J Clin Pharmacol 29: 215, 1985
Ohnhaus EE, Heidemann H, Meier J, Maurer G: Metabolism of pindolol in patients with renal failure. Eur J Clin Pharmacol 22: 423, 1982
Stone WJ, Walle T: Massive propranolol metabolite retention during maintenance hemodialysis. Clin Pharmacol Ther 28:449, 1980
Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG: Propranolol disposition in renal failure. Br J Clin Pharmacol 10: 561, 1980
Blair AD, Burgess ED, Maxwell BM, Cutler RE: Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29: 457, 1981
Singh BN, Deedwania P, Koonlawee N, Ward A, Sorkim EM: Sotalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34: 311, 1987
Kelly JG, O’Malley K: Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 22: 416, 1992
Laher MS, Kelly JG, Doyle GD et al.: Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 12(Suppl 7): S60, 1988
Buckley MM, Grant SM, Goa KL, McTavish D, Sorkin EM: Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs 39: 757, 1990
Grech-Bélangér O, Langlois S, LeBoeuf E: Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol 28: 477. 1988
Pozet N, Brazier JL, Aïssa AH et al.: Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 24: 635, 1983
Buur T, Larsson R, Regårdh CG. Aberg J: Pharmacokinetics of felodipine in chronic hemodialysis patients. J Clin Pharmacol 31: 709, 1991
Edgar B, Regardh CG, Attman PO, Aurell M, Herlitz H. Johnsson G: Pharmacokinetics of felodinine in patients with impaired renal function. Br J Clin Pharmacol 27: 67, 1989
Todd PA, Faulds D: Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 44: 251, 1992
Chandler MH, Schran HF, Cutler RE, Smith AJ. Gonasun LM, Blouin RA: The effeets of renal function on the disposition of isradipine. J Clin Pharmacol 28: 1076, 1988
Fitton A, Benfield P: Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40: 31, 1990
Schonholzer K, Marone C: Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol 42: 231, 1992
Sorkin EM, Clissold SP: Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 33: 296, 1987
Martre H, Sari R, Taburet AM, Jacobs C, Singlas E: Haemodialysis does not affect the pharmacokinetics of nifedipine. Br J Clin Pharmacol 20: 155, 1985
Sorkin EM, Clissold SP, Brogden RN: Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30: 182, 1985
Goa KL, Sorkin EM: Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 33: 123, 1987
Mikus G, Mast V, Fischer C, Machleidt C, Kuhlman U, Eichelbaum M: Pharmacokineties, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. Br J Clin Pharmacol 31: 313, 1991
Hanyok JJ, Chow MS, Kluger J, Izard MW: An evaluation of the pharmacokinetics, pharmacodynamics, anddialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 28: 831, 1988
McTavish D, Sorkin EM: Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38: 19, 1989
Mooy J, Schols M, van Baak M, van Hooff M, Muytens A, Rahn KH: Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 28: 405, 1985
Graves PE, Fenster PE, MacFarland RT, Marcus FI, Perrier D: Kinetics of digitoxin and the bis-and monodigitoxosides of digitoxigenin in renal insufficiency. Clin Pharmacol Ther 36: 607, 1984
Vohringer HF, Rietbrock N: Digitalis therapy in renal failure with special regard to digitoxin. Int J Clin Pharmacol Ther Toxicol 19: 175, 1981
Gibson TP, Nelson HA: The question of cumulation of digoxin metabolites in renal failure. Clin Pharmacol Ther 27: 219, 1980
Keller F, Molzahn M, Ingerowski R: Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution. Eur J Clin Pharmacol 18: 433, 1980
Sonnenblick M, Abraham AS, Meshulam Z, Eylath U: Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J 286: 1089, 1983
Lant A: Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs 29: 57, 1985
Lant A: Diuretics. Clinical pharmacology and therapeutic use (Part II). Drugs 29: 162, 1985
Chapron DJ, Gomolin IH, Sweeney KR: Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function. J Clin Pharmacol 29: 348, 1989
Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H: Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33: 493, 1987
Pentikäinen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Pentilla A: Bumetanide kinetics in renal failure. Clin Pharmacol Ther 37: 582, 1985
Ward A, Heel RC: Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 28: 426, 1984
Mulley BA, Parr GD, Rye RM: Pharmacokinetics of chlorthalidone. Eur J Clin Pharmacol 17: 203, 1980
Pillay VK, Schwartz FD, Aimi K, Kark RM: Transient and permanent deafness following treatment of ethacrynic acid in renal failure. Lancet 1(585), 77, 1969
Brater DC, Anderson SA, Brown-Cartwright D: Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 40: 134, 1986
Ponto LL, Schoenwald RD: Furosemide (Frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet 18: 381, 1990
Traeger A, Stein G, Sperschneider H, Keil E: Pharmacokinetic and pharmacodynemic effects of furosemide in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol 22: 481, 1984
Acchiardo SR, Skoutakis VA: Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 106: 237, 1983
Clissold SP, Brogden RN: Piretanide. A preliminary review of its pharmacodynamic and pharmcokinetic properties, and therapeutic efficacy. Drugs 29: 489, 1985
Marone C, Reubi FC, Perisic M, Lahn W: Pharmacokinetics of high doses of piretanide in moderate to severe renal failure. Eur J Clin Pharmacol 27: 589, 1984
Skluth HA, Gums JG: Spironolactone: a re-examination. DICP Ann. Pharmacother 24: 52, 1990
Niemeyer C, Hasenfub G, Wais U, Knauf H, Shafer-Korting M, Mutschler E: Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 24: 661, 1983
Fairley KF, Woo KT, Birch DF, Leaker BR, Ratnaike S: Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 26: 169, 1986
Bottorff MB, Rutledge DR, Pieper JA: Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties. Pharmacotherapy 5: 227, 1985
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS: Amrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 26: 468, 1983
Majerus TC, Dasta JF, Bauman JL, Danzinger LH, Ruffolo RR: Dobutamine; ten years later. Pharmacotherapy 9: 245, 1989
Sonnenblick EH, Frishman WH, LeJemtel TH: Dobutamine; a new synthetic cardioactive sympathetic amine. N Engl J Med 300: 17, 1979
Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G: Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol 29: 549, 1986
Young RA, Ward A: Milrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 36: 158, 1988
Bogaert MG: Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet 12: 1, 1987
Evers J, Bonn R, Boertz A et al.: Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. Eur J Clin Pharmacol 32: 503, 1987
Evers J, Krakamp B, Klimkait W et al.: Pharmacokinetics of isosorbide-5-nitrate in renal failure. Eur J Cl Pharmacol 30: 349, 1986
Pearson RM: Pharmacokinetics and response to diazoxide in renal failure. Clin Pharmacokinet 2: 198, 1977
Ludden TM, McNay JL, Shepherd AM, Lin MS: Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 7: 185, 1982
Halstenson CE, Opsahl JA, Wright CE et al.: Disposition of minoxidil in patients with various degrees of renal function. J Clin Pharmacol 29: 798, 1989
Rindone JP, Sloane EP: Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother 26: 515, 1992
Schulz V: Clinical pharmacokinetics of nitroprusside cyanide thiosulphate and thiocyanate. Clin Pharmacokinet 9: 239, 1984
Crooke ST, Comis RL, Einhorn LH, Strong JE, Broughton A, Prestayko AW: Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treat Rep 61: 1631, 1977
Ehrsson H, Hassan M, Ehrnebo M, Beran M: Busulfan kinetics. Clin Pharmacol Ther 34: 86, 1983
Elferink F, van der Vijgh WJ, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21: 57, 1988
Motzer RJ, Niedzwiecki D, Isaacs M et al.: Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 27: 234, 1990
Van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242, 1991
Newell DR, Calvert AH, Harrap KR, McElwain TJ: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol 15: 253, 1983
Blachley JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95: 628, 1981
Corden BJ, Fine RL, Ozols RF, Collins JM: Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 14: 38, 1985
Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19: 443, 1981
Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194, 1991
Wang LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in hemodialysis: application to plasma, red blood cell, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 29: 365, 1981
Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 7: 1563, 1989
Goto M, Yoshida H, Honda A et al.: Delayed disposition of adriamycin and its active metabolite in haemodialysis patients. (Letter) Eur J Clin Pharmacol 44: 301, 1993
Speth PA, van Hoesel QG, Haanen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15, 1988
Henwood JM, Brogden RN: Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438, 1990
Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215, 1989
Hollingshead LM, Faulds D: Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42: 690, 1991
Alberts DS, Chen HG, Benz D, Mason NL: Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43: 330, 1981
Österborg A, Ehrsson H, Eksborg S. Wallin I, Mellstedt H: Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. EurJ Cancer Clin Oncol 25: 899, 1989
Sand TE, Jacobsen S: Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19: 453, 1981
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094, 1983
Shen DD, Azarnoff DL: Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3: 1, 1978
Den Hartigh J, McVie JG, Van Oort WS, Pinedo HM: Pharmacokinetics of mitomycin C in humans. Cancer Res 43: 5017, 1983
Ellis ME, Weiss RB, Kuperminc M: Nephrotoxicity of lomustine: a case report and literature review, Cancer Chemother Pharmacol 15: 174, 1985
Oliverio VT: Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep 413, 1973
Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49: 494, 1970
Hall-Craggs M, Brenner DE, Vigorito RD, Sutherland JC: Acute renal failure and renal tubular squamous metaplasia following treatment with streptozocin. Hum Pathol 13: 597, 1982
Buckley MM, Goa KL: Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451, 1989
Owellen RJ, Hartke CA, Hains FO: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597, 1977
Clissold SP, Edwards C: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214, 1988
Ferner RE, Chaplin S: The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 12: 379, 1987
Palmer KJ, Brogden RN: Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46: 92, 1993
Lebovitz HE: Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 63, 1985
Feldman JM: Glyburide: a second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 43, 1985
Brogden RN, Heel RC: Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 34: 350, 1987
Guba EA, Abel SR, Golper TA: Practical guidelines for drug therapy in dialysis: lipid lowering agents. Semin Dial 2: 186, 1989
Sherrard DJ, Goldberg AB, Haas LB, Brunzell JD: Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 25: 219, 1980
Tse FL, Jaffe JM, Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: 630, 1992
Manninen V, Malkonen M, Esailo A: Gemfibrozil treatment of dyslipidaemias in renal failure with uraemia or in the nephrotic syndrome. Res Clin Forums 4: 113, 1982
Corpier CL, Jones PH, Suki WN et al.: Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260: 239, 1988
Henwood JM, Heel RC: Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36: 429, 1988
Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F: Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287, 1988
McTavish D, Sorkin EM: Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42: 65, 1991
Buckley MM, Goa KL, Price AH, Brogden RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 37: 761, 1989
Mauro VF: Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24: 195, 1993
Kampmann JP, Hansen JM: Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 6: 401, 1981
Jansson R, Lindstrom B, Dahlberg PA: Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 10: 443, 1985
Lauritsen K, Laursen LS, Rask-Madsen J: Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin Pharmacokinet 19: 11, 1990
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 25: 451, 1983
Milne RJ, Heel RC: Ondansetron: therapeutic use as an antiemetic. Drugs 41: 574, 1991
Lin JH: Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 20: 218, 1991
Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8: 463, 1983
Larsson R, Bodemar G, Norlander B: Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 15: 153, 1979
Larsson R, Erlanson P, Bodemar G et al.: The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 13: 163, 1982
Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF: Pharmacokinetics of cimetidine in patients undergoing hemodialysis. Nephron 34: 159, 1983
Krishna DR, Klotz U: Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15: 205, 1988
Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 21: 178, 1991
Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H: Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol 26: 315, 1988
Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR: Disposition of famotidine in renal insufficiency. J Clin Pharmacol 27: 782, 1987
Price AH, Brogden RN: Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 36: 521, 1988
Saima S, Echizen H. Yoshimoto K, Ishizaki T: Hemofiltrability of histamine H2-receptor antagonist, nizatidine, and its metabolites in patients with renal failure. J Clin Pharmacol 33: 324, 1993
Comstock TJ, Sica DA, Harford A, Eshelman F: Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. Nephron 52: 15, 1989
Grant SM, Langtry HD, Brogden RN: Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37: 801, 1989
Meffin PJ, Grgurinovich N, Brooks PM, Miners JO, Cochran M, Stranks G: Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol 16: 731. 1983
Zech PY, Chau NP, Pozet N, Labeeuw M, Hadj-Aissa A: Ranitidine kinetics in chronic renal impairment. Clin Pharmacol Ther 34: 667, 1983
Barradell LB, Faulds D, McTavish D: Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 44: 225, 1992
Jones JB, Bailey RT: Misoprostol: a prostaglandin E1 analog with antisecretory and cytoprotective properties. DICP, Ann Pharmacother 23: 276, 1989
Howden CW: Clinical pharmacology of omeprazole. Clin Pharmacokinet 20: 38, 1991
Naesdal J, Andersson T, Bodemar G et al.: Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 40: 344, 1986
Burgess E, Muruve D, Audette R: Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency. Am J Med 92: 471, 1992
Roxe DM, Mistovich M, Barch DH: Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 13: 194, 1989
Eadie MJ: Anticonvulsant drugs. An update. Drugs 27: 328, 1984
Bertilsson L, Tomson T: Clinical pharmacokinets and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 11: 177, 1986
Lee CS, Wang LH, Marbury TC, Bruni J, Peschalski RJ: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 17: 429, 1980
Marbury TC, Lee CS, Perchalski RJ, Wilder BJ. Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 38: 1757, 1981
Dasgupta A, Abu-Alfa A: Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Am J Clin Pathol 98: 19, 1992
Czajka PA, Anderson WH, Christoph RA, Banner W Jr: A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol 20: 565, 1980
Lee CS, Marbury TC, Perchalski RT, Wilder BJ: Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol 22: 301, 1982
Brewster D, Muir NC: Valproate plasma protein binding in the uremic condition. Clin Pharmacol Ther 27: 76, 1980
Zaccara G, Messori A, Moroni F: Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 15: 367, 1988
Cedarbaum JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 141, 1987
Yen KC, August TF, Bush DF et al.: Pharmacokinetics and bioavailability of sinemet CR: ta summary of human studies. Neurology 39(Suppl 2): 25, 1989
Burke RE, Fahn S: Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 18: 35, 1985
Hande K, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47, 1984
Murrel GA, Rapeport WG: Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 11: 343, 1986
Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 18: 264, 1991
Levy M, Spino M, Read SE: Colchicine: a state of the art review. Pharmacotherapy 11: 196, 1991
Cunningham RF, Israili ZH, Dayton PG: Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6: 135, 1981
Verbeeck RK, Blackburn JL, Loewen GR: Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8: 297, 1983
Todd PA, Sorkin EM: Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35: 244, 1988
Eriksson LO, Wahlin-boll E, Odar-Cederlof I, Lindholm L, Melander A: Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal. Eur J Clin Pharmacol 36: 165, 1989
Balfour JA, Buckley MM: Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs 42: 274, 1991
Cefali EA, Poynor WJ, Sica D, Cox S: Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. J Clin Pharmacol 31: 808, 1991
Albert KS, Gernaat CM: Pharmacokinetics of ibuprofen. Am J Med 77: 40, 1984
Skoutakis VA, Acchiardo SR, Carter CA, Wojciechowski NJ, Straun AB, Meyer MC: Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug Intell Clin Pharm 20: 956, 1986
Williams RL, Upton RA: The clinical pharmacology of ketoprofen. J Clin Pharmacol 28(Suppl 12): S13, 1988
Brocks DR, Jamali F: Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet 23: 415, 1992
Todd PA, Clissold SP: Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs 40: 91, 1990
Verbeeck RK, Richardson CJ, Blocka KL: Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789, 1986
Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillan CL: Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33: 527, 1993
Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS: Auranofin: a preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs 27: 378, 1984
Blocka KL, Paulus HE, Furst DE: Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet 11: 133, 1986
Levy NB: Psychopharmacology in patients with renal failure. Int J Psychiatr Med 20: 325, 1990
Preskorn SH, Othmer SC: Evaluation of bupropion hydrochloride: the first of a new class of atypical anti-depressants. Pharmacotherapy 4: 20, 1984
Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L: Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36: 138, 1984
Benfield P, Heel RC, Lewis SP: Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 481, 1986
Christensen JH, Andreasen F, Jansen J: Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand 27: 513, 1983
Garzone PD, Kroboth PD: Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16: 337, 1989
Schmith VD, Piraino B, Smith RB, Kroboth PD: Alprazolam in end-stage renal disease: I. Pharmacokinetics. J Clin Pharmacol 31: 571, 1991
Ochs HR, Rauh HW, Greenblatt DJ: Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 37: 100, 1984
Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM: Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet 3: 381, 1978
Morrison G, Chiang ST, Koepke HH, Walker BR: Effect of renal impairment and hemodialysis on lorazepam kinetics. Clin Pharmacol Ther 35: 646, 1984
Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR: The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59: 390, 1983
Ochs HR, Oberem U, Greenblatt DJ: Nitrazepam clearance unimpaired in patients with renal insufficiency. J Clin Psychopharmacol 12: 183, 1992
Greenblatt DJ, Murray TG, Audet PR, Locniskar A, Koepke HH, Walker BR: Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron 34: 234, 1983
Ankier SI, Goa KL: Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35: 42, 1988
Kroboth PD, Smith RB, Sorkin MI et al.: Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration. Clin Pharmacol Ther 36: 379, 1984
Roth T, Roehrs TA, Zorick FJ: Pharmacology and hypnotic efficacy of triazolam. Pharmacotherapy 3: 137, 1983
Loo JC, Midha KK, McGilveray IJ: Pharmacokinetics of chlorpromazine in normal volunteers. Communications in Psychopharmacology 4: 121, 1980
Taylor G, Houston JB, Shaffer J, Mawer G: Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 15: 287, 1983
Lieberman JA, Cooper TB, Suckow RF et al.: Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37: 301, 1985
Sandoz M, Vandel S, Vandel B et al.: Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 26: 227, 1984
Tasset JJ, Singh S, Pesce AJ: Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Ther Drug Monit 7: 255, 1985
McTavish D, Benfield P: Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136, 1990
DeVane CL, Savett M, Jusko WJ: Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. Eur J Clin Pharmacol 19: 61, 1981
Faulkner RD, Senekjian HO, Lee CS: Hemodialysis of doxepin and desmethyldoxepin in uremic patients. Artif Organs 8: 151, 1984
Potter WZ, Calil HM, Sutfin TA et al.: Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31: 393, 1982
Dawling S, Lynn K, Rosser R, Braithwaite R: Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther 32: 322, 1982
Ziegler VE, Biggs JT, Wylie LT et al.: Protriptyline kinetics. Clin Pharmacol Ther 23: 580, 1978
Caccia S, Vigano GL, Mingardi G et al.: Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 14: 171, 1988
Fitton A, Heel RC: Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722, 1990
Froemming JS, Lam YW, Jann MW, Davis CM: Pharma-cokinetics of haloperidol. Clin Pharmacokinet 17: 396, 1989
Singer I: Lithium and the kidney. Kidney Int 19: 374, 1981
Luisier PA, Schultz P, Dick P: The pharmacokinetics of lithium in normal humans: expected and unexpected observations in view of basic kinetic principles. Pharmacopsychiatry 20: 232, 1987
Mahoney G, Wolfram KM, Cochetto D, Bjorsson TD: Dipyridamole kinetics. Clin Pharmacol Ther 31: 330, 1982
Kandrotas RJ: Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 22: 359, 1992
Grierson DS, Bjornsson TD: Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity. Clin Pharmacol Ther 41: 304, 1987
Pedersen AK, Jakobsen P, Kampmann JP, Hansen JM: Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 7: 42, 1982
McTavish D, Faulds D, Goa KL: Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40: 238, 1990
Collen D, Lijnen HR, Todd PA, Goa KL: Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 38: 346, 1989
Holford NH: Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 11: 483, 1986
Paton DP, Webster DR: Clinical pharmacokinetics of H1 — receptor antagonists (The antihistamines). Clin Pharmacokinet 10: 477, 1985
Krstenansky PM, Cluxton RJ: Astemizole: a long-acting, nonsedating antihistamine. Drugs Intell Clin Pharm 21: 947, 1987
Richards DM, Brogden RM, Heel RC, Speight TM, Avery GS: Oxatomide: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 210, 1984
Carter CA, Wojciechowski NJ, Hayes JM, Skoutakis VA. Rickman LA: Terfenadine, a nonsedating antihistamine. Drug Intell Clin Pharm 19: 812, 1985
Morgan DJ: Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet 18: 270, 1990
Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs 35: 22, 1988
Lee CCU, Wang LH, Majeske BL, Marbury TC: Pharmacokinetics of dyphylline elimination by uremic patients. J Pharmacol Exp Ther 217: 340, 1981
Bauer LA, Bauer SP, Blouin RA: The effect of acute and chronic renal failure on theophylline clearance. J Clin Pharmacol 22: 65, 1982
Kradjan WA, Martin TR, Delaney CJ, Blair AD, Cutler RE: Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. Nephron 32: 40, 1982
Chan GL, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7: 165, 1987
Salemans J, Hoitsma AJ, De Abreu RA et al.: Pharmacokinetics of azathioprine and 6-mercaptopurine after oral administration of azathioprine. Clin Transplant 1: 217, 1987
Kawai S, Ichikawa Y, Homma M: Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metal 60: 848, 1985
Sherlock JE, Letteri JM: Effect of hemodialysis on methylprednisolone plasma levels. Nephron 18: 208, 1977
Frey BM, Frey FJ: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19: 126, 1990
Follath F, Wenk M, Vozeh S et al.: Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34: 638, 1983
Putcha L, Griffith DP, Feldman S: Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi. Eur J Clin Pharmacol 28: 439, 1985
Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: report of international registry. Am J Kidney Dis 18: 660, 1991
Verpooten GA, D’Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME: Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 7: 931, 1992
Silver MR, Kroboth PD: Pentoxifylline in end-stage renal disease. Drug Intell Clin Pharm 21: 976, 1987
Ward A, Clissold SP: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50, 1987
Reetze-Bonorden P, Böhler J, Keller E: Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 24: 362, 1993
Kroh UF, Dehne M, El Abed K, Feubner KD, Hofmann W, Lennartz H: Drug dosage during continuous hemofiltration: pharmacokinetics and practical implications, in Contrib Nephrol, Vol 93, edited by Sieberth HG, Mann H, Stummvoll HK, Basel, Karger, 1991, p 127
Goldman M, Vanherweghem J: Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. Adv Nephrol Necker Hosp 19: 315, 1990
Mailloux LU, Bellucci AG, Wilkes BM et al.: Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 18: 326, 1991
Manian FA, Stone WJ, Alford RH: Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis 12: 236, 1990
Gilbert DN: Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35: 399, 1991
Wood CA, Norton DR, Kohlhepp SJ et al.: The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 158: 13, 1988
Johnson CA, Zimmerman SW, Rogge M: The pharmacokinetics of antibiotics used to treat peritoneal dialysis-associated peritonitis. Am J Kidney Dis 4: 3, 1984
Keane WF, Everett ED, Golper TA et al.: Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. Perit Dial Int 13: 14, 1993
Humes HD: Aminoglycoside nephrotoxicity. Kidney Int 33: 900, 1988
Cameron JS: Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med 66: 97, 1988
Shouval D, Ligumsky M, Ben-Ishay D: Effect of co-trimoxazole on normal creatinine clearance. Lancet i(8058): 244, 1978
Agodoa LY, Held PJ, Port FK: Causes of death, in US Renal Data System, USRDS 1993 Annual Data Report, Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. 1993, p 49
Parving HH, Smidt UM, Hommel E et al.: Effective anti-hypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 22: 188, 1993
Castelli WP: Epidemiology of coronary heart disease: The Framingham Study. Am J Med 76: 4, 1984
Fer MF, McKinney TD, Richardson RL, Hande RR, Oldham RK, Greco FA: Cancer and the kidney: renal complications of neoplasms. Am J Med 71: 704, 1981
Narins RG, Carley M, Bloom EJ, Harrison DS: The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 10: 556, 1990
Adrogué HJ: Glucose homeostasis and the kidney. Kidney Int 42: 1266, 1992
Alvestrand A, Mujagic M, Wajngot A, Efendic S: Glucose intolerance in uremic patients: the relative contributions of impaired β-cell function and insulin resistance. Clin Nephrol 31: 175, 1989
Hager SR: Insulin resistance of uremia. Am J Kidney Dis 14: 272, 1989
Wideröe TE, Smeby LC, Berg KJ, Jorstad S, Svartas TM: Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23: 22, 1983
Attma PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573, 1993
Cheung AK, Wu LL, Kablitz C, Leypoldt JK: Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22: 271, 1993
Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 43: 410, 1993
Golper TA: Therapy for uremic hyperlipidemia. Nephron 38: 217, 1984
D’Amico G, Gentile MG: Treatment of hyperlipidemia in human renal disease. Miner Electrolyte Metab 19: 196, 1993
Orwoll ES: The milk-alkali syndrome: current concepts. Ann Intern Med 97: 242, 1982
Fraser CL, Arieff AI: Nervous system complications in uremia. Ann Intern Med 109: 143, 1988
Clive DM, Stoff FS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310: 563, 1984
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Golper, T.A., Marx, M.A., Shuler, C., Bennett, W.M. (1996). Drug Dosage in Dialysis Patients. In: Jacobs, C., Kjellstrand, C.M., Koch, K.M., Winchester, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-36947-1_30
Download citation
DOI: https://doi.org/10.1007/978-0-585-36947-1_30
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-3610-5
Online ISBN: 978-0-585-36947-1
eBook Packages: Springer Book Archive